Today, Neil George, editor of By George, discusses the hot-button topic of oil fracking and explores alternative companies that offer alternative solutions.
SPEAKER 1: My guest today is Neil George. Thanks for joining us. Neil thanks for being here. It’s so good to see you again.
NEIL: Nancy, it’s a pleasure. I’m always thrilled to be on the Moneyshow.com network.
SPEAKER 1: Thank you. Let’s talk about your recent columns about beyond fracking. I mean fracking is kind of a hot spot with people these days.
NEIL: It has been Nancy and a lot of people are making a lot of money, a lot of oil companies, especially smaller and mid-size firms have gone into areas throughout the country and therefore have been able to extract a lot more oil and gas. A lot of these companies are in the master limited partnerships, MLPs. They have been generating a lot of income, helping out investors, but at the same time, Nancy, we’ve also had a lot of concerns over some of the potential environmental impacts…
Top 10 Cheapest Companies To Invest In 2015: CDI Corporation(CDI)
CDI Corp. provides engineering and information technology project outsourcing solutions and professional staffing services primarily in the United States, the United Kingdom, and Canada. It operates in four segments: ES, MRI, Anders, and ITS. The ES segment provides engineering, design, project management, staffing, and outsourcing solutions to oil, gas, refining, alternative energy, power generation and energy transmission, chemicals, and heavy manufacturing industries; engineering, design, logistics, and staffing services to the defense industry, primarily in marine design, systems development, and military aviation support; engineering, design, project management, staffing, and facility start-up services to pharmaceutical, bio-pharmaceutical, and regulated medical services industries; and architecture, civil and environmental engineering, communication technology, and consulting services to governmental, educational, and private industry customers. The MRI segment opera tes as a global franchisor that does business as MRINetwork and provides the use of its trademarks, business systems, and training and support services to its franchisees who engage in the search and recruitment of executive, technical, professional, and managerial personnel for employment by their customers. It also provides training, implementation services, and back-office services to enable franchisees to pursue staffing opportunities. The Anders segment provides contract and permanent placement candidates to customers in the areas of architecture, building services, rail, commercial and industrial construction, consulting engineering, facilities management, interior design, surveying, and town planning. The ITS segment offers various information technology related services, which include staffing augmentation, permanent placement, outsourcing, and consulting. The company was founded in 1950 and is based in Philadelphia, Pennsylvania.
Advisors' Opinion:- [By Rich Smith]
Philadelphia-based CDI Corp. (NYSE: CDI ) has won a $36 million contract to provide watercraft engineering and marine services to the U.S. Navy.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CDI (NYSE: CDI ) , whose recent revenue and earnings are plotted below.
Hot Up And Coming Companies To Watch For 2014: Titan Company Ltd (TITAN)
Titan Company Limited, formerly Titan Industries Limited, is engaged in manufacturing of watches/accessories, jewelry, precision engineering and eyewear. The Company has four divisions: watches/accessories, jewelry, precision engineering and eyewear. As of March 31, 2012, the Company had 332 World of Titan stores. As of March 31, 2012, the Company had over three business units in Bangalore, India, a manufacturing unit at Hosur and three assembly plants located in the north of India. The brands under the watches/accessories division include: Titan, Sonata, Fastrack, Xylys and others. Tanishq is Titan�� line of jewelry with a range of jewelry, studded with diamonds or colored gems in 18-karat gold, 22-karat gold and platinum jewelry. Under eyewear division, there is a brand named Titan Eye plus. The precision engineering division includes machine building and automation solutions and tooling solutions. In March 2013, Titan Properties Ltd. was amalgamated with the Company. Advisors' Opinion:- [By James Miller Phd]
Peers like Microsoft Corp. (MSFT) and Oracle Corp. (ORCL) present strong competition in the could-based CRM market, and have been enhancing their companies through various acquisitions such as recently acquired Nimbula, Eloqua Inc., RightNow Technologies and Taleo Corp from Oracle, or MarketingPilot and Netbreeze from Microsoft. Competition is moreover expected to increase with the introduction of Microsoft Dynamics CRM software (Titan). Nevertheless, Salesforce has also been strengthening its product portfolio and expanding within the cloud based CRM services.
Hot Up And Coming Companies To Watch For 2014: Vanguard Natural Resources LLC(VNR)
Vanguard Natural Resources, LLC, through its subsidiaries, engages in the acquisition and development of oil and natural gas properties in the United States. Its properties are located in the southern portion of the Appalachian Basin, primarily in southeast Kentucky and northeast Tennessee; the Permian Basin, primarily in west Texas and southeastern New Mexico; and south Texas. As of December 31, 2010, the company had estimated proved reserves of 69.3 million barrels of oil equivalent, as well as working interests in 2,270 net productive wells. Vanguard Natural Resources, LLC was founded in 2006 and is based in Houston, Texas.
Advisors' Opinion:- [By Matt DiLallo]
The problem, though, is finding that right deal at the right price. Vanguard Natural Resources (NASDAQ: VNR ) for example reviews about 150 acquisition candidates each year and whittles that down to about 50 that are evaluated more deeply. Since its IPO, the company has only closed 18 transaction as few meet the stringent requirements needed to move the needle. It's a similar story at BreitBurn which screened 500 opportunities last year but just closed seven deals for about $600 million.�
- [By Matt DiLallo]
Last year Vanguard Natural Resources (NASDAQ: VNR ) changed its distribution policy and in so doing changed the game for oil and gas producing MLPs. The new monthly distribution policy enabled the company's income-seeking investors to better match their monthly cash outflows with monthly inflows from Vanguard. It was such a unique strategy that the company even trademarked the tag line that the company is "The Monthly Distribution MLP."
- [By Robert Rapier]
During this past week�� joint monthly web chat for subscribers of The Energy Strategist�and MLP Profits, we received several questions about Vanguard Natural Resources (Nasdaq: VNR). So let�� get to know this energy income play a little better.
- [By Matt DiLallo]
Oil and gas producer, Vanguard Natural Resources (NASDAQ: VNR ) is out with its first-quarter earnings. The company, known for its monthly distribution to investors, is one of a growing number of oil and gas production companies structured as an MLP/LLC. This makes the high yielder a favorite of income-starved investors. Let's take a quick look to ensure that income won't be drying up anytime soon.
Hot Up And Coming Companies To Watch For 2014: Marten Transport Ltd (MRTN)
Marten Transport, Ltd. is a temperature-sensitive truckload carrier. The Company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. It operates throughout the United States and in parts of Canada and Mexico. The Company operates in two segments: Truckload and Logistics. During the year ended December 31, 2011, approximately 81% of its truckload revenue resulted from hauling temperature-sensitive products and 19% from hauling dry freight. Its long-haul traffic lanes are between the Midwest and the West Coast, Southwest, Southeast, and the East Coast, as well as from California to the Pacific Northwest. It provides regional truckload carrier services in the Southeast, West Coast, Midwest, South Central and Northeast regions.
The Company derives truckload revenue from fuel surcharges, loading and unloading activities, equipment detention and other ancillary services. Its operating revenue also includes revenue reported within its Logistics segment, which consists of revenue from its internal brokerage and intermodal operations, and through its 45% interest in MW Logistics, LLC (MWL), a third-party provider of logistics services to the transportation industry. Brokerage services involve arranging for another company to transport freight for the Company�� customers, while it retains the billing, collection and customer management responsibilities. Intermodal services involve the transport of its trailers on railroad flatcars for a portion of a trip, with the balance of the trip using its tractors or, to a lesser extent, contracted carriers. It focuses on large food and consumer-packaged goods companies whose products require temperature-sensitive services and who ship multiple truckloads per week. As of December 31, 2011, its customers were General Mills and Kraft.
As of December 31, 2011, the Company operated a fleet of 2,281 tractors, including 2,233 company owned tractors and 48 t! ractors supplied by independent contractors. The average age of its company owned tractor fleet at December 31, 2011 was approximately 2.6 years. As of December 31, 2011, it operated a fleet of 4,124 trailers. Most of its trailers are equipped with Thermo-King refrigeration units, air ride suspensions and anti-lock brakes. The average age of its trailer fleet as of December 31, 2011 was approximately 2.4 years.
Advisors' Opinion:- [By Monica Gerson]
Marten Transport (NASDAQ: MRTN) is estimated to post its Q3 earnings at $0.23 per share on revenue of $168.28 million.
CSX (NYSE: CSX) is expected to post its Q3 earnings at $0.43 per share on revenue of $2.95 billion.
Hot Up And Coming Companies To Watch For 2014: Lufkin Industries Inc.(LUFK)
Lufkin Industries, Inc. manufactures and supplies oilfield and power transmission products for use in energy infrastructure and industrial applications. The company operates through two segments, Oil Field and Power Transmission. The Oil Field segment manufactures and services artificial lift products, including reciprocating rod lift equipment, including air-balanced, beam-balance, crank-balanced, Mark II Unitorque, and hydraulic units. It also transports and repairs pumping units; and refurbishes used pumping units. In addition, this segment designs, manufactures, installs, and services computer control equipment and analytical services for artificial lift equipment, as well as operates an iron foundry to produce castings for new pumping units. Further, the Oil Field segment provides gas lift, plunger lift, and completion equipment. The Power Transmission segment designs, manufactures, and services speed increasing and reducing gearboxes. It also manufactures capital spa res for customers in conjunction with the production of new gearboxes, as well as produces parts for after-market service. In addition, this segment provides on and off-site repair and service for its own products, and also those manufactured by other companies. Further, the Power Transmission segment is involved in analysis, design, and manufacture of precision, custom-engineered tilting-pad bearings and related components for high-speed turbo equipment operating in critical duty applications, as well as services, repairs, and upgrades turbo-expander process units for air and gas separation. The company markets its products and services primarily in the United States, Europe, Canada, Latin America, the Middle East, and north Africa. Lufkin Industries, Inc. was founded in 1902 and is based in Lufkin, Texas.
Advisors' Opinion:- [By Marc Courtenay]
On April 8th, we learned that General Electric (GE) would be acquiring Lufkin Industries (LUFK). The deal is one of the three largest in the oilfield machinery and equipment industry during the past decade, and sets the stage for further acquisitions in this sector. Investors should start considering which companies might be next.
Hot Up And Coming Companies To Watch For 2014: Galena Biopharma Inc (GALE)
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.
The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.
The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.
Advisors' Opinion:- [By Sean Williams]
The waiting game
The tables are clearly stacked against small biotech companies developing cancer drugs. History has shown that few (if any) have successfully had the Food and Drug Administration approve a late-stage cancer drug. While mid-stage trials of Galena Biopharma's (NASDAQ: GALE ) HER2-targeting breast cancer vaccine have been promising thus far, the chances of an approval seem a long way off. - [By James E. Brumley]
The last two weeks have been absolutely fantastic ones for Galena Biopharma Inc. (NASDAQ:GALE). Shares have soared from $2.37 to the current price of $3.32 - a 40% pop - rewarding investors who had been patiently waiting through late October for the runup to take hold. Congratulations if that's you. But, if that was you, then now might be a great time to take the money and run with the trade, as GALE looks poised to make a sizeable pullback. More on that in a moment.
No comments:
Post a Comment